Activation of death receptors offers a possible mechanism of bypassing sites of resistance and engaging the caspase machinery of apoptosis directly Death receptor pathways also cooperate in unknown ways with other signals to amplify apoptosis. For several highly resistant mesothelioma lines, including M28, the TNF-related apoptosis inducing ligand (TRAIL) induces apoptosis, an apoptosis greatly amplified by concurrent treatment either with chemotherapeutic agents, such as etoposide, or with proteasome inhibitors In our proposal, the mechanism(s) by which TRAIL-induced apoptosis can be amplified and the relevance of these findings to in vivo models of mesothelioma will be explored. First, specific pathways by which etoposide amplifies TRAIL-induced apoptosis will be investigated, with particular attention to the role of mitochondria, by blocking mitochondrial pathways with overexpression of Bcl-XL or dominant negative caspase 9, by testing mitochondrial sensitivity to the death receptor signal tBid, and by analysis of mitochondrial BH3-containing proteins. The possible role of the stress activated pathway, JNK/SAPK, will be examined in M28 cells with stable blockade with dominant negative JNK1 and/or JNK2 or with stimulation of JNK by MEKK4 Secondly, the mechanism(s) by which proteasome inhibitors amplify TRAIL-induced apoptosis will be investigated Proteasome inhibitors, unlike chemotherapeutic agents, increase expression of the TRAIL receptor, DR5. This suggests a novel role for the proteasome in the degradation and regulation of expression of a death receptor. The role of the proteasome in DR5 degradation, the specificity for DR5 and the contribution of increased DR5 to the amplified apoptosis will be determined. Finally, the in vitro findings will be tested lot their relevance to in vivo mesothelioma models In nude mice with subcutaneous tumors of M28 cells, systemic TRAIL and either chemotherapy, proteasome inhibitors or both given systemically will be assessed for effects on tumor size, apoptotic index and expression of the DR5 receptor In human mesothelioma tumors from individual patients studied as tumor fragment spheroids, response to TRAIL and/or etoposide, proteasome inhibitors or both will also be determined Understanding the mechanisms of amplification of TRAIL-induced apoptosis can provide insight into the means by which malignant cells evade apoptosis and ways to bypass those sites of resistance and thereby improve treatment strategies

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA095671-01A1
Application #
6573014
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
2003-03-12
Project End
2007-02-28
Budget Start
2003-03-12
Budget End
2004-02-29
Support Year
1
Fiscal Year
2003
Total Cost
$269,077
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Yang, Tsung-Ming; Barbone, Dario; Fennell, Dean A et al. (2009) Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 41:14-23
Bidlingmaier, Scott; He, Jiang; Wang, Yong et al. (2009) Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 69:1570-7
Barbone, Dario; Yang, Tsung-Ming; Morgan, Jeffrey R et al. (2008) Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283:13021-30
Wilson, Shannon M; Barbone, Dario; Yang, Tsung-Ming et al. (2008) mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 39:576-83
An, Feng; Drummond, Daryl C; Wilson, Shannon et al. (2008) Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther 7:569-78
Araya, Jun; Cambier, Stephanie; Markovics, Jennifer A et al. (2007) Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest 117:3551-62
Hassan, Raffit; Broaddus, V Courtney; Wilson, Shannon et al. (2007) Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 13:7166-71
Abayasiriwardana, Keith S; Barbone, Dario; Kim, Ki-Up et al. (2007) Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther 6:2766-76
Pespeni, Melissa H; Hodnett, Maki; Abayasiriwardana, Keith S et al. (2007) Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway. Cancer Res 67:2865-71
Kim, Ki-Up; Wilson, Shannon M; Abayasiriwardana, Keith S et al. (2005) A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33:541-8

Showing the most recent 10 out of 13 publications